EDS UK is proud to be partnering with Symprove, a UK gut health company, on a pioneering research study exploring the impact of a gut microbiome supplement in people with Ehlers-Danlos syndromes (EDS) and Hypermobility Spectrum Disorders (HSD).
The partnership began when Dr Asma Fikree, Consultant Neurogastroenterologist at University College Hospital, approached EDS UK with an opportunity to support research into the relationship between gut health and EDS and HSD. Recognising the significant impact that gastrointestinal symptoms can have on people living with these conditions, EDS UK was keen to help facilitate a study that could contribute valuable evidence and improve understanding in an under-researched area.
Working alongside Dr Fikree and Symprove, EDS UK helped connect the research team with our community and support recruitment for a UK-wide, 12-week study. The research is investigating the impact of Symprove’s water-based live bacteria supplement in people with EDS and HSD – the first study of its kind in this population.
The response from our community was extraordinary. Interest far exceeded expectations, and recruitment was oversubscribed, leading to applications closing early. This overwhelming demand demonstrated both the community’s willingness to engage in research and the urgent need for greater understanding of gastrointestinal symptoms and symptom management in EDS and HSD.
As part of the partnership, EDS UK has supported participant recruitment and engagement, helping ensure that people with lived experience are represented in research that could ultimately shape future approaches to care and symptom management.
The study is currently ongoing, with results expected in late 2026. We look forward to sharing the findings with our community and continuing to build partnerships that advance research, increase understanding and improve the lives of people living with EDS and HSD.